| 0 (0%) | 09-27 09:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.62 | 1-year : | 43.94 |
| Resists | First : | 32.2 | Second : | 37.62 |
| Pivot price | 31.72 |
|||
| Supports | First : | 31.36 | Second : | 30.85 |
| MAs | MA(5) : | 31.98 |
MA(20) : | 31.6 |
| MA(100) : | 30.63 |
MA(250) : | 30.83 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 72.7 |
D(3) : | 76  |
| RSI | RSI(14): 61.3 |
|||
| 52-week | High : | 32.31 | Low : | 28.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PWS ] has closed below upper band by 21.8%. Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.05 - 32.24 | 32.24 - 32.43 |
| Low: | 31.39 - 31.62 | 31.62 - 31.84 |
| Close: | 31.68 - 32.02 | 32.02 - 32.34 |
Fri, 26 Sep 2025
Acadia drops development of carbetocin in PWS - The Pharma Letter
Thu, 25 Sep 2025
PWS-related hyperphagia drug ACP-101 fails to meet trial goals - Prader-Willi Syndrome News
Thu, 25 Sep 2025
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - TradingView
Wed, 24 Sep 2025
Acadia Gives Up In PWS After Another ACP-101 Phase III Miss - insights.citeline.com
Wed, 24 Sep 2025
Acadia pulls plug on Prader-Willi drug after trial flop - FirstWord Pharma
Wed, 24 Sep 2025
Acadia Pharmaceuticals: Reeling After PWS Failure - Downgrading To Hold (NASDAQ:ACAD) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|